Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/20/2024 | $2.00 → $35.00 | Hold → Buy | Jefferies |
| 9/13/2021 | $3.50 | Neutral | HC Wainwright & Co. |
| 9/2/2021 | Outperform → Market Perform | William Blair |
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv
Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde
Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously
HC Wainwright & Co. initiated coverage of Assembly Biosciences with a rating of Neutral and set a new price target of $3.50
William Blair downgraded Assembly Biosciences from Outperform to Market Perform
SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
424B5 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
10-Q - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. American Software The Trade: American Software, Inc. (NASDAQ:AMSWA) Director James B Miller Jr acquired a total of 3,718 shar
HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing First participants dosed in Phase 1b trial evaluating ABI-5366 in individuals with recurrent genital herpes with interim data expected in first half of 2025Phase 1b trial for ABI-4334, a next-generation highly potent capsid assembly modulator candidate, ongoing in participants with chronic HBV with interim data expected by end of yearABI-1179 and ABI-6250 candidates on track to enter clinic by end of year SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences
– ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both dosing schedules will be explored in the Phase 1b portion of the study – – Screening of participants with recurrent genital herpes is now underway for Phase 1b – SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced positive interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoin
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a next-generation capsid assembly modulator (CAM) candidate in development for the treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV (cHBV) infection is a leading cause of chronic liver disease and liver transplants globally, with the World Health Organization estimating that over one million people died in 2022 from HBV-related causes. Current treatments are lifelong and reduce, but d